Skip to main content
OpenTrials
Completed

NCT Number: NCT06170515

BGM and HbA1c POC Device Evaluation

This study aims to assess analytical performance of four BGMs and four HbA1c POC devices in comparison to suitable comparator or reference methods, with the view to evaluate performance in the hands of trained users, as well as intended users who are unfamiliar with the system (lay users, for BGMs only). System usability will also be assessed for all BGMs (including lancing devices) and HbA1c devices.

Completed

Looking for future studies?

Notify Me

Key information

Age range

13 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Sihanouk Hospital Centre of Hope, Phnom Penh, Cambodia

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Arm 1:

  • 13-17 years, diagnosed with diabetes and able to manage condition independently (ideally at least 10% of total Arm 1 population)

•≥18 years, diagnosed with diabetes

  • Able and willing to provide informed consent/assent
  • Naïve to the SMBG use of the investigational devices
  • 10% naïve to any SMBG (defined as not having performed any SMBG in the last 24 months)
  • Haematocrit within 20-60%
  • Pre-screen BGM result qualifies for inclusion in any of the five glucose concentration ranges based on % of subjects required to meet the target number per concentration range

Arm 2:

•≥18 years

  • Able and willing to provide informed consent
  • Diagnosed or not diagnosed with diabetes
  • Haemoglobin values ≥ 8g/dL
  • Pre-screen HbA1c result qualifies for inclusion in the target HbA1c range and % of subjects required for the mid-range values

Exclusion criteria

Arm 1:

  • <13 years
  • 13-17 years and not diagnosed with diabetes or unable to manage condition independently
  • Previous use of investigational BGM for SMBG
  • Haematocrit outside normal range
  • Pre-screen BGM result falling in a glucose concentration range that already has sufficient participants.

Arm 2:

  • <18 years
  • Haemoglobin value < 8g/dL
  • Pre-screen HbA1c result falling in a concentration range that already has sufficient participants.

Treatment and study plan

CareSens N-Eco (i-Sens), • CareSens N-Premier (i-Sens), CodeFree (SD Biosensor), GlucoNavii GDH (SD Biosensor)

Diagnostic Test

BGM Test

Affinion (Abbott), HbA1c 501 (HemoCue), A1Care (iSens), DCA Vantage (Siemens)

Diagnostic Test

HbA1c Test

Primary outcomes

  1. BGM Performace

    Time frame: 1 year

    For BGMs: Performance accuracy is based on ISO 15197 criteria, mean relative bias, 95% limits of agreement, and regression slopes of each BGM with respect to two independently validated comparator BGMs (each investigational BGM will be compared to each comparator BGMs independently).

  2. HbA1c Performance

    Time frame: 1 year

    For HbA1c: Performance accuracy is based on regression slopes, mean relative bias, 95% limits of agreement, and of each HbA1c device versus the reference method and the concordance between capillary and venous blood results.

Secondary outcomes

  1. Comprehension

    Time frame: 1 year

    Proportion of label comprehension, system usability and result/symbol interpretation scale rating per question across all lay users stratified by BGM and lancing device; Total system usability score scale per BGM and lancing device.

  2. Usability

    Time frame: 1 year

    Proportion of system usability and result/symbol interpretation scale rating per question across all lay users stratified by BGM and lancing device; Total system usability score scale per BGM and lancing device.

  3. Interpretation

    Time frame: 1 year

    Proportion of result/symbol interpretation scale rating per question across all lay users stratified by BGM and lancing device; Total system usability score scale per BGM and lancing device

  4. Number of errors as observed

    Time frame: 1 year

    Number and type of errors observed; proportion of error type observed per BGM and lancing device .

  5. Type of errors as observed

    Time frame: 1 year

    Number and type of errors observed; proportion of error type observed per BGM and lancing device .

  6. Proportion of label comprehension

    Time frame: 1 year

    Proportion of system usability scale rating per question across all healthcare professionals, stratified by HbA1c POC device; Total system usability score scale per HbA1c POC device

  7. Number of errors as displayed.

    Time frame: 1 year

    Number and type of errors as displayed on the BGM or HbA1c POC devices, stratified by type of user (BGMs only) and device

  8. Type of errors as displayed

    Time frame: 1 year

    Number and type of errors as displayed on the BGM or HbA1c POC devices, stratified by type of user (BGMs only) and device

Sponsors and collaborators

Lead sponsor

Foundation for Innovative New Diagnostics, Switzerland

Other

Registry information

Official study title

Performance Evaluation of Blood Glucose Meters and HbA1c Point-of-care Devices

Important dates

Study start
2023
Primary completion
2023
Study completion
2024
First posted
Dec 14, 2023
Registry last updated
Sep 17, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.